BIOE.US Bio Essence Corporation
- Market cap
- USD 25.3M
- P/E
- 15.7x
- P/B
- 10.80x
- ROE
- 18.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BIOE.US undervalued?
Graham numberBIOE.US trades 174.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio Essence Corporation fundamental analysis
No fundamental analysis for Bio Essence Corporation yet.
Bio Essence Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio Essence Corporation
Bio Essence Corporation engages in manufacturing and distributing health supplement products. It also offers original equipment manufacturing, and private label services for dietary supplements, vitamins, and herbal nutrition products. Bio Essence Corporation was incorporated in 2000 and is headquartered in Irvine, California.
Full company profileBio Essence Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bio Essence Corporation annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.34M | 985K | 826K | 959K | 888K | 622K | 552K | 324K | 1.90M | 2.06M |
| Gross Profit | 388K | 362K | 172K | 227K | 298K | 328K | 277K | 217K | 1.43M | 1.24M |
| Operating Income | -1.73M | -1.50M | -1.72M | -833K | -858K | -511K | -789K | -459K | 900K | 448K |
| EBITDA | -1.71M | -1.46M | -1.67M | -517K | -560K | -497K | -765K | -1.56M | 900K | 586K |
| Net Income | -1.76M | -1.46M | -1.70M | -596K | -648K | -810K | -972K | -1.31M | 896K | 433K |
| EPS | -0.06 | -0.05 | -0.05 | -0.02 | -0.02 | -0.02 | -0.03 | -0.03 | 0.02 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 1.89M | 1.02M | 2.29M | 1.85M | 1.70M | 1.55M | 2.66M | 281K | 422K | 4.00M |
| Total Liabilities | 358K | 853K | 3.38M | 3.63M | 4.13M | 4.79M | 4.32M | 3.25M | 2.50M | 1.71M |
| Shareholders' Equity | 1.53M | 169K | -1.09M | -1.78M | -2.43M | -3.24M | -1.66M | -2.97M | -2.07M | 2.29M |
| Cash & Short-term Investments | 714K | -64.7K | 16.2K | 5.33K | 303.00 | 6.26K | 114.00 | 1.37K | 0.00 | 202K |
| Total Debt | - | 125K | 2.27M | 2.96M | 3.96M | 4.62M | 3.48M | 2.70M | 1.56M | 1.51M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -2.10M | -831K | -897K | -733K | -1.29M | -703K | -1.03M | 624K | 1.57M | -962K |
| Capital Expenditure | 91.6K | 96.7K | 27.7K | 7.37K | 119K | 59.1K | 3.61K | 5.00 | 3.00 | 0.00 |
| Free Cash Flow | -2.20M | -928K | -925K | -740K | -1.41M | -707K | -1.03M | 624K | 1.57M | -962K |
| Ratios | ||||||||||
| ROE | -115.2% | -860.9% | - | - | - | - | - | - | - | 18.9% |
| ROA | -93.3% | -142.7% | -74.2% | -32.3% | -38.1% | -52.3% | -36.5% | -465.7% | 212.1% | 10.8% |
| Net Profit Margin | -131.5% | -148.2% | -206.1% | -62.2% | -72.9% | -130.3% | -176.2% | -404.0% | 47.2% | 21.0% |
| Debt to Equity | - | 0.74x | - | - | - | - | - | - | - | 0.66x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bio Essence Corporation dividends
Bio Essence Corporation has not paid dividends in the last 9 fiscal years.
Who owns Bio Essence Corporation
- Insiders 63.92%
- Institutions 0.00%
- Public & others 36.08%
- Shares outstanding 53.8M
- Free float 19.4M
Bio Essence Corporation company profile
- Company name
- Bio Essence Corporation
- Ticker
- BIOE.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4
- Fiscal year end
- December
- Address
- 2955 Main Street, Irvine, CA, United States, 92618
- Phone
- 949 706 9966
- Website
- bioessencecorp.com
About Bio Essence Corporation
Bio Essence Corporation engages in manufacturing and distributing health supplement products. It also offers original equipment manufacturing, and private label services for dietary supplements, vitamins, and herbal nutrition products. Bio Essence Corporation was incorporated in 2000 and is headquartered in Irvine, California.
Bio Essence Corporation management
6- Ms. Yin Yan J.D., M.B.A.CEO, Controller, Chief Accounting Officer & Chairman of the Board · born 1976
- Mr. William E. SlussCFO & Director · born 1955
- Mr. Tuan TranVice President of Operations · born 1974
- Yuling HuangAccounting Manager
- Ji Ping RongOperation Manager
- Wenwen HeAccounting Assistant